Invion Stock

Invion EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invion (IVX.AX) as of Aug 26, 2026 is -3.30 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.57 M AUD — a change of -27.85% (higher).

EBITDA

-3.30 MAUD

YoY

-27.85%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invion is 2026 -3.30 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invion was 2025 -4.57 M AUD. It decreases by -27.85% higher compared to the previous year.

The Invion EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-648,600.00 AUD
Jan 1, 2019
-2.21 M AUD
Jan 1, 2020
-748,600.00 AUD
Jan 1, 2021
-1.29 M AUD
Jan 1, 2022
-1.90 M AUD
Jan 1, 2023
-931,700.00 AUD
Jan 1, 2024
-4.57 M AUD
Jan 1, 2025
-3.30 M AUD
The Invion EBITDA history
YEAREBITDAYoY
-3.30 MAUD-27.85%
-4.57 MAUD+390.69%
-931,700.00AUD-50.94%
-1.90 MAUD+46.71%
-1.29 MAUD+72.91%
-748,600.00AUD-66.09%
-2.21 MAUD+240.39%
-648,600.00AUD-2.61%
-666,000.00AUD-71.74%
-2.36 MAUD-78.61%
-11.02 MAUD+97.50%
-5.58 MAUD
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invion is -3.30 M AUD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Invion changed from -4.57 M AUD to -3.30 M AUD, representing a -27.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Invion since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Invion historically and in real time.

Access this data via the Eulerpool API

Income Statement — Invion

All Key Metrics — Invion